AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 9051389
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg ALA daily for 4 months
Trial: 8330461
Drug: Quinine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinine (oral doses)
Trial: 8330461
Drug: Quinidine (oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Quinidine (oral doses)
Trial: 2451815
Drug: Flupirtine (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flupirtine (80 mg i.v.)
Trial: 2451815
Drug: Pentazocine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pentazocine (30 mg i.v.)
Trial: 2551070
Drug: 75 XaI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 75 XaI U/kg b.w. twice daily Logiparin
Trial: 2551070
Drug: 150 XaI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 XaI U/kg b.w. once daily Logiparin
Trial: 2551070
Drug: Logiparin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Logiparin treatment
Trial: 23677816
Drug: Pharmaceutical care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical care intervention including medication review, education on osteoporosis, risk factors, lifestyle modifications, goals of therapy, side effects, and importance of medication adherence at months 0, 3, 6, and 12
Trial: 19824379
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy plus ovestin (daily intravaginal administration for 2 weeks, then twice a week)
Trial: 15208504
Drug: 99mTc‐L,L‐EC scan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 99mTc‐L,L‐EC scan
Trial: 11588692
Drug: Ramoplanin 100
RxNorm normalized name: RAMOPLANIN
DrugBank: Ramoplanin (DB04952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramoplanin 100 mg
Trial: 11588692
Drug: Ramoplanin 400
RxNorm normalized name: RAMOPLANIN
DrugBank: Ramoplanin (DB04952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramoplanin 400 mg
Trial: 9613276
Drug: Epidural blockade
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blockade with 0.9% saline (16 ml) prior to incision and 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to closure.
Trial: 9613276
Drug: Epidural blockade
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural blockade with 0.5% bupivacaine (15 ml) + fentanyl 50 micrograms (1 ml) prior to incision and 0.9% saline prior to closure.
Trial: 27349220
Drug: Low-volume oral
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-volume oral sulfate solution (OSS)
Trial: 30400725
Drug: 4-L polyethylene
RxNorm normalized name: polyethylene glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4-L polyethylene glycol (PEG)
Trial: 26297239
Drug: Discharge medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Discharge medication counselling and medication review by a clinical pharmacist
Trial: 23947774
Drug: Structured communication
RxNorm normalized name: LIPID,STRUCTURED (FROM SUNFLOWER OIL)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured communication approach (DIALOG) with principles of solution-focused therapy, 6 meetings over 6 months
Trial: 21324674
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (ZA) 4 mg intravenous every 3 months for 2 years (arm A)
Trial: 17296236
Drug: 0.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/kg ketamine administered into the tonsillar region
Trial: 17296236
Drug: 2 ml
RxNorm normalized name: ethanol 2 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 ml 0.9% saline administered into the tonsillar region
Trial: 3141220
Drug: hFSH/hMG on
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hFSH/hMG on days 3 and 4 of the cycle followed by two ampules of hMG daily
Trial: 3141220
Drug: Constant daily
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constant daily dose of 2 ampules of hMG
Trial: 26439234
Drug: Exercise with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise with Animal-Assisted Therapy (E+ATT; n = 8)
Trial: 21723684
Drug: Low volume
RxNorm normalized name: CONNECTOR,LOW VOLUME,ENFIT MOOG INFINITY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low volume contrast media (0.5 ml/kg) and low kV (100) in group B
Trial: 21723684
Drug: Standard volume
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard volume contrast media (1 ml/kg) and standard kV (120) in group A
Trial: 19114966
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E (400 IU) daily for five days during two menstrual cycles
Trial: 19114966
Drug: Placebo (identical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (identical in appearance to vitamin E) daily for five days during two menstrual cycles
Trial: 15322504
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (dalteparin)
Trial: 9509802
Drug: Tirilazad mesylate
RxNorm normalized name: tirilazad mesylate
DrugBank: Tirilazad (DB13050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tirilazad mesylate (6 mg/kg per day)
Trial: 2646753
Drug: Piroxicam (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piroxicam (40 mg on days 1 and 2, additional 20 mg on day 3 if necessary)
Trial: 2646753
Drug: Naproxen (1,000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxen (1,000 mg on days 1 and 2, additional 500 mg on day 3 if necessary)
Trial: 23543447
Drug: Adefovir (ADV)
DrugBank: Adefovir (DB13868)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adefovir (ADV) monotherapy
Trial: 23543447
Drug: Lamivudine (LAM)
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine (LAM) monotherapy
Trial: 23543447
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (LAM + ADV)
Trial: 15756221
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) plus 70% lactulose (1 mL/kg/day)
Trial: 15756221
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus 70% lactulose (1 mL/kg/day)
Trial: 8859237
Drug: Midazolam (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.1 mg/kg bolus followed by saline infusion)
Trial: 8859237
Drug: Propofol (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (1.0 mg/kg bolus followed by 65 micrograms/kg/min infusion)
Trial: 8396100
Drug: Amoxycillin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (30 mg/kg/day for 10 days in three divided doses; children > 20 kg received 250 mg tid daily)
Trial: 3523741
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg X 2)
Trial: 28795342
Drug: Cholecalciferol therapy
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol therapy (50,000 IU once a week for 12 weeks)
Trial: 16164121
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 100 mg/day
Trial: 12078940
Drug: Benazepril 10
RxNorm normalized name: benazepril 10 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril 10 mg + Amlodipine 5 mg (BZ+AM)
Trial: 12078940
Drug: Captopril 50
RxNorm normalized name: captopril 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril 50 mg + Hydrochlorothiazide 25 mg (CP+HT)
Trial: 11008323
Drug: Glutathione (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glutathione (5 g immediately before cisplatin)
Trial: 11008323
Drug: Control (2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (2000 ml electrolyte infusion before and 2000 ml normal saline after cisplatin)
Trial: 8536820
Drug: Voglibose 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 0.5 mg
Trial: 8536820
Drug: Voglibose 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 1.0 mg
Trial: 8536820
Drug: Voglibose 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 1.0 mg (3 times daily for 7 days)
Trial: 8536820
Drug: Voglibose 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 2.0 mg
Trial: 8536820
Drug: Voglibose 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Voglibose 5.0 mg
Trial: 2621331
Drug: HCG injection
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HCG injection for ovulation induction
Trial: 859943
Drug: Daily application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily application of INH 400 mg, rifampicin 450-600 mg, and myambutol 25 mg/kg for the first two months followed by 15 mg/kg
Trial: 859943
Drug: Intermittent application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent application three times weekly of INH 600 mg, rifampicin 750 mg, and myambutol 30 mg/kg for the first two months followed by 20 mg/kg
Trial: 859943
Drug: Intermittent application
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent application twice weekly of INH 800 mg, rifampicin 900 mg, and myambutol 50 mg/kg for the first two months followed by 30 mg/kg
Trial: 859943
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated by daily application of Str one gram for 6-8 months, INH 5-10 mg/kg and PAS 12-15 g daily
Trial: 859943
Drug: All groups
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All groups (A, B1, B2) compared to classical mode of treatment
Trial: 19320276
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg itraconazole capsule
Trial: 10952406
Drug: Transdermal fentanyl
RxNorm normalized name: fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Transdermal fentanyl plaster
Trial: 10952406
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release morphine tablets
Trial: 12603640
Drug: rizatriptan 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rizatriptan 10‐mg standard tablets
Trial: 12603640
Drug: rizatriptan 10‐mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rizatriptan 10‐mg orally disintegrating tablets
Trial: 12603640
Drug: Oral usual
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral usual care medications
Trial: 8697550
Drug: 2M2V (mivacurium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2M2V (mivacurium 0.15 mg.kg‐1 plus vecuronium 0.1 mg.kg‐1)
Trial: 2662837
Drug: Fenoterol syrup
RxNorm normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenoterol syrup
Trial: 29551699
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of IMT + FES
Trial: 27089049
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with tegafur–uracil (UFT)
Trial: 17319428
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 10 mg + 15 microg fentanyl
Trial: 17319428
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 11 mg + 15 microg fentanyl
Trial: 17319428
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 12 mg + 15 microg fentanyl
Trial: 17319428
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 13 mg + 15 microg fentanyl
Trial: 17319428
Drug: Hyperbaric bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric bupivacaine 14 mg (no fentanyl)
Trial: 15003297
Drug: Ultrasound-guided BTX-A
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Ultrasound-guided BTX-A injections (Group A, n=8)
Trial: 15003297
Drug: Blind BTX-A
RxNorm normalized name: BTX-A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Blind BTX-A injections (Group B, n=7)
Trial: 26179482
Drug: Tofogliflozin 10
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 10 mg
Trial: 26179482
Drug: Tofogliflozin 40
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 40 mg
Trial: 26179482
Drug: Tofogliflozin (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofogliflozin (all doses)
Trial: 21595861
Drug: Silicone oil
RxNorm normalized name: SILICONE OIL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silicone oil injection
Trial: 21595861
Drug: Balanced salt
RxNorm normalized name: Balanced Salt Solution
DrugBank: Magnesium chloride (DB09407)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Balanced salt solution (BSS) injection
Trial: 14671164
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GH/m(2).d
Trial: 14671164
Drug: 2 mg
RxNorm normalized name: iodine 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg GH/m(2).d
Trial: 14671164
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg GH/m(2).d and 2 mg GH/m(2).d
Trial: 1643677
Drug: Spinal anaesthesia
RxNorm normalized name: Bos taurus spinal cord preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spinal anaesthesia (4 ml 0.5% isobaric bupivacaine)
Trial: 1643677
Drug: Epidural anaesthesia
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural anaesthesia (15 ml of 0.5% bupivacaine)
Trial: 6375709
Drug: glaucine 30
RxNorm normalized name: glaucine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: glaucine 30 mg
Trial: 6375709
Drug: dextromethorphan 30
RxNorm normalized name: DEXTROMETHORPHAN 30MG/5ML LIQUID
FDA approved: no
EMA approved: no
PMDA approved: no
Description: dextromethorphan 30 mg
Trial: 22924353
Drug: Oxalic acid-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxalic acid-based preparation
Trial: 8539008
Drug: Objects presented
RxNorm normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objects presented in the same category (sequential and simultaneous trials)
Trial: 8539008
Drug: Objects presented
RxNorm normalized name: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine
DrugBank: Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine (DB15813)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Objects presented in mixed categories (sequential and simultaneous trials)
Trial: 8539008
Drug: Sequential presentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential presentation of objects
Trial: 2379297
Drug: Rheum palmatum
RxNorm normalized name: RHEUM PALMATUM ROOT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rheum palmatum L
Trial: 29932230
Drug: 200‐mg selenium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200‐mg selenium yeast tablets
Trial: 23063567
Drug: Intravenous silibinin
RxNorm normalized name: Silibinin
DrugBank: Silibinin (DB09298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous silibinin (SIL)
Trial: 18375894
Drug: MA 20
RxNorm normalized name: LENVIMA 20mg Daily Dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 20 mg
Trial: 18375894
Drug: MA 40
RxNorm normalized name: Colace Micro-Enema 40 MG/ML Enema
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MA 40 mg
Trial: 10895743
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine (up to 300 mg)
Trial: 1442579
Drug: Simvastatin 10
RxNorm normalized name: simvastatin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 10 mg once daily
Trial: 31309775
Drug: IV ILO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ILO once monthly
Trial: 31309775
Drug: Not requiring
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not requiring therapy with IV ILO
Trial: 30249366
Drug: Gemigliptin 50
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin 50 mg once a day
Trial: 30249366
Drug: Metformin 1000
RxNorm normalized name: metformin 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin 1000 mg BID
Trial: 30249366
Drug: Gemigliptin +
RxNorm normalized name: gemigliptin
DrugBank: Gemigliptin (DB12412)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gemigliptin + Metformin
Trial: 25234012
Drug: Part-time patching
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part-time patching for 3 hours daily for 5 months
Trial: 25234012
Drug: Observation (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation (no treatment for 6 months)
Trial: 20230254
Drug: Antofloxacin hydrochloride
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antofloxacin hydrochloride 200 mg
Trial: 20230254
Drug: Antofloxacin hydrochloride
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antofloxacin hydrochloride 300 mg
Trial: 20230254
Drug: Antofloxacin hydrochloride
RxNorm normalized name: danofloxacin
DrugBank: Danofloxacin (DB11393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antofloxacin hydrochloride 400 mg
Trial: 17266089
Drug: Early intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early intervention (EI) with intraarticular methylprednisolone injections
Trial: 17266089
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (CT) with nonsteroidal antiinflammatory drugs
Trial: 17266089
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (CT) with sulfasalazine
Trial: 31518174
Drug: TAM +
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TAM + OFS (5 years of Tamoxifen with 2 years of ovarian function suppression using monthly goserelin administration)
Trial: 28698350
Drug: nanocurcumin (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nanocurcumin (40 mg capsules, 2 per day for 3 months)
Trial: 28698350
Drug: placebo (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (40 mg capsules, 2 per day for 3 months)
Trial: 20368202
Drug: Glyburide plus
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide plus muraglitazar 2.5 mg
Trial: 20368202
Drug: Glyburide plus
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide plus muraglitazar 5 mg
Trial: 20368202
Drug: Glyburide plus
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide plus muraglitazar (both doses)
Trial: 15367726
Drug: Oxcarbazepine (1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxcarbazepine (1200 mg)
Trial: 29351799
Drug: MedDiet plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedDiet plus extravirgin OO, 20-30 g/day
Trial: 17851756
Drug: Decongestive therapy
RxNorm normalized name: Qlearquil Nasal Decongestant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decongestive therapy
Trial: 7938858
Drug: Caudal puncture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caudal puncture and anesthesia with 2.5 mg/kg bupivacaine 1:200,000
Trial: 7938858
Drug: Lumbar puncture
RxNorm normalized name: Lumbar Puncture 18g 3.5"
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumbar puncture at L4‐L5 and 1.25 mg/kg of bupivacaine
Trial: 7938858
Drug: Epidural catheter
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural catheter in the caudal space up to L4‐L5 and 1.25 mg/kg of bupivacaine administered through the catheter
Trial: 2836324
Drug: Imuthiol (Na
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imuthiol (Na diethyldithiocarbamate) adjuvant therapy
Trial: 28353023
Drug: GUM Hydral
RxNorm normalized name: Chloral Hydrate
DrugBank: Chloral hydrate (DB01563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GUM Hydral mouthwash plus gel
Trial: 28353023
Drug: Biotene Oralbalance
RxNorm normalized name: BIOTENE
DrugBank: Sodium fluorophosphate (DB09484)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotene Oralbalance mouthwash plus gel
Trial: 12752890
Drug: Intravenous conjugated
RxNorm normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous conjugated equine oestrogen (25 mg)
Trial: 11082823
Drug: Active transdermal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active transdermal nicotine patch